Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study - European Journal of Cancer

Updated Data From Clinical Trials on Nivolumab/Ipilimumab in Advanced Melanoma - The ASCO Post

Metastatic Melanoma Therapies OPDIVO® (nivolumab) + YERVOY® (ipilimumab)

Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Rationale for combining ipilimumab and nivolumab. CTLA-4: Cytotoxic

A new era of proactive melanoma therapy: hit hard, hit early - Haas - 2018 - British Journal of Dermatology - Wiley Online Library

Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis - ScienceDirect